Javascript must be enabled to continue!
Abstract B61: Effects of anti-obesity dietary supplement DHEA on serum DHEA, DHEA-S, IGF-1 and IGFBP-3 in DMBA-induced breast cancer model.
View through CrossRef
Abstract
Obesity has been epidemic in the US for over two decades. Obesity has been linked to the risk of development of various cancers, including breast cancer. Dehydroepiandrosterone (DHEA) is an over-the-counter dietary supplement used as an anti-cancer agent and anti-obesity supplement. The objectives of this study were to investigate the long-term effects of obesity and DHEA treatment on body weight gain and serum DHEA, DHEA-S, IGF-1and IGFBP-3 using 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumor model. Forty-three six-week-old obese female Zucker rats were used. Rats were randomly assigned and had ad libitum access to water and a diet of either chow (2016) as a control diet or chow with the addition of DHEA at a concentration of 6 g/kg of chow as a DHEA diet. All rats were orally gavaged at age 50 days with 65 mg DMBA/kg body weight and were sacrificed 155 days post-DMBA treatment. Fifty-five percent (55%) of the control diet group developed mammary tumors, while no tumors were detected in the DHEA diet group (P<0.001). Obese rats fed the DHEA diet gained significantly less weight (P<0.001) and had an increased (P<0.001) serum DHEA and DHEA-S compared to control rats. Also, obese DHEA-Fed rats had significantly (P<0.001) lower serum IGF-1 and IGF-BP3. Our results suggest that DHEA treatment can reduce body weight gain by lowering serum IGF-1 and IGFBP-3 which might protects against breast cancer development caused by obesity. Also, this results suggests that breast cancer risk may be due to genetic predisposition to obesity might be related to body weight gain. It also suggests that these individuals could potentially reduce their risk by actively combating the weight gain. Supported by ABI to RH.
Citation Format: Reza Hakkak, Soheila Korourian. Effects of anti-obesity dietary supplement DHEA on serum DHEA, DHEA-S, IGF-1 and IGFBP-3 in DMBA-induced breast cancer model. [abstract]. In: Proceedings of the Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2012 Oct 27-30; San Diego, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(10 Suppl):Abstract nr B61.
American Association for Cancer Research (AACR)
Title: Abstract B61: Effects of anti-obesity dietary supplement DHEA on serum DHEA, DHEA-S, IGF-1 and IGFBP-3 in DMBA-induced breast cancer model.
Description:
Abstract
Obesity has been epidemic in the US for over two decades.
Obesity has been linked to the risk of development of various cancers, including breast cancer.
Dehydroepiandrosterone (DHEA) is an over-the-counter dietary supplement used as an anti-cancer agent and anti-obesity supplement.
The objectives of this study were to investigate the long-term effects of obesity and DHEA treatment on body weight gain and serum DHEA, DHEA-S, IGF-1and IGFBP-3 using 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumor model.
Forty-three six-week-old obese female Zucker rats were used.
Rats were randomly assigned and had ad libitum access to water and a diet of either chow (2016) as a control diet or chow with the addition of DHEA at a concentration of 6 g/kg of chow as a DHEA diet.
All rats were orally gavaged at age 50 days with 65 mg DMBA/kg body weight and were sacrificed 155 days post-DMBA treatment.
Fifty-five percent (55%) of the control diet group developed mammary tumors, while no tumors were detected in the DHEA diet group (P<0.
001).
Obese rats fed the DHEA diet gained significantly less weight (P<0.
001) and had an increased (P<0.
001) serum DHEA and DHEA-S compared to control rats.
Also, obese DHEA-Fed rats had significantly (P<0.
001) lower serum IGF-1 and IGF-BP3.
Our results suggest that DHEA treatment can reduce body weight gain by lowering serum IGF-1 and IGFBP-3 which might protects against breast cancer development caused by obesity.
Also, this results suggests that breast cancer risk may be due to genetic predisposition to obesity might be related to body weight gain.
It also suggests that these individuals could potentially reduce their risk by actively combating the weight gain.
Supported by ABI to RH.
Citation Format: Reza Hakkak, Soheila Korourian.
Effects of anti-obesity dietary supplement DHEA on serum DHEA, DHEA-S, IGF-1 and IGFBP-3 in DMBA-induced breast cancer model.
[abstract].
In: Proceedings of the Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2012 Oct 27-30; San Diego, CA.
Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(10 Suppl):Abstract nr B61.
Related Results
Serum levels of insulin-like growth factor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients
Serum levels of insulin-like growth factor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients
Osteopenia has been ascribed to diabetics without residual insulin secretion and high insulin requirement. However, it is not known if this is partially due to disturbances in the ...
Expression, purification and characterization of the structure and disulfide linkages of insulin-like growth factor binding protein-4
Expression, purification and characterization of the structure and disulfide linkages of insulin-like growth factor binding protein-4
Insulin-like growth factor binding protein-4 (IGFBP-4), like the other five IGFBPs, is a critical regulator of the activity of insulin-like growth factor (IGF)-I and IGF-II. Howeve...
Expression of insulin-like growth factor binding protein-3 in HELLP syndrome
Expression of insulin-like growth factor binding protein-3 in HELLP syndrome
Abstract
Objective
To investigate the expression of insulin-like growth factor binding protein-3(IGFBP-3) in HELLP syndro...
Data from Circulating Insulin-Like Growth Factors and IGF-Binding Proteins in PSA-Detected Prostate Cancer: The Large Case–Control Study ProtecT
Data from Circulating Insulin-Like Growth Factors and IGF-Binding Proteins in PSA-Detected Prostate Cancer: The Large Case–Control Study ProtecT
<div>Abstract<p>Circulating insulin-like growth factor-I (IGF-I) has been studied extensively in prostate cancer, but there is still little information about IGFs and I...
Data from Circulating Insulin-Like Growth Factors and IGF-Binding Proteins in PSA-Detected Prostate Cancer: The Large Case–Control Study ProtecT
Data from Circulating Insulin-Like Growth Factors and IGF-Binding Proteins in PSA-Detected Prostate Cancer: The Large Case–Control Study ProtecT
<div>Abstract<p>Circulating insulin-like growth factor-I (IGF-I) has been studied extensively in prostate cancer, but there is still little information about IGFs and I...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Differential expression of IGF-I and IGF-binding protein-1 and -2 in periportal and perivenous zones of rat liver
Differential expression of IGF-I and IGF-binding protein-1 and -2 in periportal and perivenous zones of rat liver
IGF-I has important roles in regulating growth and metabolism. Circulating IGF-I is bound to specific binding proteins (IGFBP-1 to -6), with hepatocytes containing IGF-I, IGFBP-1 a...
Desmoid-Type Fibromatosis of The Breast: A Case Series
Desmoid-Type Fibromatosis of The Breast: A Case Series
Abstract
IntroductionDesmoid-type fibromatosis (DTF), also called aggressive fibromatosis, is a rare, benign, locally aggressive condition. Mammary DTF originates from fibroblasts ...

